At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCVX Vaxcyte, Inc.
Trading 05-21 11:26:32 EDT
46.80
-0.37
-0.78%
High47.45Low46.51Vol313.09K
Open46.87D1 Closing47.17Amplitude1.99%
Mkt Cap6.74BTradable Cap5.47BTotal Shares144.00M
T/O14.67MT/O Rate0.27%Tradable Shares116.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Vaxcyte Down Over 10%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk
Dow Jones  ·  05-08
Vaxcyte Down Over 10%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (EVO), Vaxcyte (PCVX) and ACADIA Pharmaceuticals (ACAD)
TIPRANKS  ·  05-08
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (EVO), Vaxcyte (PCVX) and ACADIA Pharmaceuticals (ACAD)
Vaxcyte Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  05-07
Vaxcyte Inc reports results for the quarter ended December 31 - Earnings Summary
Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate
Benzinga  ·  05-07
Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate
Vaxcyte Q1 net loss widens to $320.6 million; R&D expenses jump to $312.8 million
Reuters  ·  05-07
Vaxcyte Q1 net loss widens to $320.6 million; R&D expenses jump to $312.8 million
BRIEF-Vaxcyte Q1 Operating Expenses USD 345.85 Million
Reuters  ·  05-07
BRIEF-Vaxcyte Q1 Operating Expenses USD 345.85 Million
Vaxcyte COO Jim Wassil disposes of USD 127,869 common shares
Reuters  ·  05-02
Vaxcyte COO Jim Wassil disposes of USD 127,869 common shares
Vaxcyte announces upcoming annual shareholder meeting
Reuters  ·  04-24
Vaxcyte announces upcoming annual shareholder meeting
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)
TIPRANKS  ·  04-15
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)
Vaxcyte SVP Finance Elvia Cowan disposes of USD 180,000 common shares
Reuters  ·  04-09
Vaxcyte SVP Finance Elvia Cowan disposes of USD 180,000 common shares
Vaxcyte to present at Needham Virtual Healthcare Conference fireside chat
Reuters  ·  04-08
Vaxcyte to present at Needham Virtual Healthcare Conference fireside chat
Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment
Simply Wall St.  ·  04-05
Vaxcyte (PCVX) Valuation Check As VAX-31 Phase 3 OPUS Trials Reach Full Enrollment
Vaxcyte COO Jim Wassil disposes of common shares worth $0.1 million
Reuters  ·  04-04
Vaxcyte COO Jim Wassil disposes of common shares worth $0.1 million
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer
Reuters  ·  03-25
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer
Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults
Reuters  ·  03-23
Vaxcyte completes enrollment in OPUS-1 and OPUS-2 Phase 3 trials of VAX-31 in about 5,300 adults
Vaxcyte Inc - Opus-3 Phase 3 Results Expected in First Half of 2027
THOMSON REUTERS  ·  03-23
Vaxcyte Inc - Opus-3 Phase 3 Results Expected in First Half of 2027
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
GlobeNewswire  ·  03-23
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative
Simply Wall St.  ·  03-22
Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet
Simply Wall St.  ·  03-21
Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet
TIPRANKS  ·  03-19
Vaxcyte reports positive VAX-31 phase 1/2 adult data published in The Lancet

Introduction

Company Name.
Vaxcyte, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Issue price:
--